HC Wainwright Forecasts Lower Earnings for Vera Therapeutics

Vera Therapeutics, Inc. (NASDAQ:VERA) – Analysts at HC Wainwright lowered their Q2 2025 earnings estimates for shares of Vera Therapeutics in a note issued to investors on Wednesday, May 7th. HC Wainwright analyst A. He now anticipates that the company will post earnings per share of ($0.90) for the quarter, down from their previous forecast of ($0.81). HC Wainwright currently has a “Buy” rating and a $75.00 target price on the stock. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Vera Therapeutics’ Q3 2025 earnings at ($0.87) EPS, Q4 2025 earnings at ($0.84) EPS, FY2025 earnings at ($3.42) EPS, Q1 2026 earnings at ($0.78) EPS, Q2 2026 earnings at ($0.74) EPS, Q3 2026 earnings at ($0.77) EPS, Q4 2026 earnings at ($0.22) EPS and FY2026 earnings at ($2.51) EPS.

A number of other equities research analysts have also recently issued reports on the company. JPMorgan Chase & Co. dropped their price objective on Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 4th. Wedbush cut their price target on shares of Vera Therapeutics from $34.00 to $26.00 and set a “neutral” rating for the company in a research note on Wednesday. Wolfe Research started coverage on shares of Vera Therapeutics in a research note on Tuesday, February 4th. They set an “outperform” rating and a $49.00 price objective on the stock. The Goldman Sachs Group initiated coverage on shares of Vera Therapeutics in a research note on Tuesday, January 28th. They issued a “buy” rating and a $58.00 target price for the company. Finally, Guggenheim boosted their price target on Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $63.33.

Vera Therapeutics Stock Performance

VERA opened at $21.77 on Friday. The business’s 50-day simple moving average is $24.22 and its 200 day simple moving average is $34.68. Vera Therapeutics has a 52-week low of $18.53 and a 52-week high of $51.61. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The firm has a market capitalization of $1.39 billion, a PE ratio of -8.34 and a beta of 1.28.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same period in the previous year, the company earned ($0.56) EPS.

Hedge Funds Weigh In On Vera Therapeutics

Large investors have recently made changes to their positions in the company. Avoro Capital Advisors LLC grew its holdings in Vera Therapeutics by 30.2% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company’s stock valued at $237,247,000 after buying an additional 1,300,410 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Vera Therapeutics by 11.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,377,049 shares of the company’s stock valued at $185,107,000 after acquiring an additional 437,940 shares in the last quarter. FMR LLC increased its position in Vera Therapeutics by 9.6% during the fourth quarter. FMR LLC now owns 3,053,126 shares of the company’s stock worth $129,117,000 after acquiring an additional 267,842 shares during the period. Vanguard Group Inc. raised its stake in Vera Therapeutics by 14.3% in the 4th quarter. Vanguard Group Inc. now owns 2,949,564 shares of the company’s stock worth $124,737,000 after purchasing an additional 369,387 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP boosted its holdings in Vera Therapeutics by 31.0% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 1,437,339 shares of the company’s stock valued at $60,785,000 after purchasing an additional 340,488 shares during the period. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.